Literature DB >> 7902301

Use of fertility drugs in the United States, 1973 through 1991.

D K Wysowski1.   

Abstract

There has been a 1.9-fold increase over nearly 20 years in the number of dispensed prescriptions for CC. Since its marketing in 1967, CC has been the major drug prescribed for infertility. In 1973, there were an estimated 390,000 prescriptions for this drug; by 1991, 731,000. From 1984 through 1991, chorionic gonadotropin, menotropins, and urofollitropin together accounted for no more than one third of the market share of the gonadotrophin class of drugs, whose primary indication is treatment of infertility. These drugs were primarily prescribed by obstetrician gynecologists to white females, 20 to 39 years of age, for treatment of infertility of unspecified origin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902301     DOI: 10.1016/s0015-0282(16)56417-6

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  9 in total

Review 1.  The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment.

Authors:  Mohamed F M Mitwally; Robert F Casper; Michael P Diamond
Journal:  Reprod Biol Endocrinol       Date:  2005-10-04       Impact factor: 5.211

Review 2.  Use of fertility drugs and risk of ovarian cancer.

Authors:  Brenda Diergaarde; Michelle L Kurta
Journal:  Curr Opin Obstet Gynecol       Date:  2014-06       Impact factor: 1.927

3.  Use of fertility drugs and risk of ovarian cancer: results from a U.S.-based case-control study.

Authors:  Michelle L Kurta; Kirsten B Moysich; Joel L Weissfeld; Ada O Youk; Clareann H Bunker; Robert P Edwards; Francesmary Modugno; Roberta B Ness; Brenda Diergaarde
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-15       Impact factor: 4.254

4.  Fertility drugs and the risk of breast and gynecologic cancers.

Authors:  Louise A Brinton; Vikrant V Sahasrabuddhe; Bert Scoccia
Journal:  Semin Reprod Med       Date:  2012-04-27       Impact factor: 1.303

5.  Fertility drug use and mammographic breast density in a mammography screening cohort of premenopausal women.

Authors:  Brian L Sprague; Amy Trentham-Dietz; Mary Beth Terry; Hazel B Nichols; Andrew J Bersch; Diana S M Buist
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

Review 6.  Pharmacological interventions for the induction of ovulation.

Authors:  J A Collins; E G Hughes
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

7.  The risk of female malignancies after fertility treatments: a cohort study with 25-year follow-up.

Authors:  R Kessous; E Davidson; M Meirovitz; R Sergienko; E Sheiner
Journal:  J Cancer Res Clin Oncol       Date:  2015-09-04       Impact factor: 4.553

8.  Fertility drug use and the risk of ovarian tumors in infertile women: a case-control study.

Authors:  Albert Asante; Phoebe H Leonard; Amy L Weaver; Ellen L Goode; Jani R Jensen; Elizabeth A Stewart; Charles C Coddington
Journal:  Fertil Steril       Date:  2013-04-01       Impact factor: 7.329

Review 9.  In-Vitro Fertilization Impact on the Risk of Breast Cancer: A Review Article.

Authors:  Dariush D Farhud; Shaghayegh Zokaei; Mohammad Keykhaei; Mehdi Hedayati; Marjan Zarif Yeganeh
Journal:  Iran J Public Health       Date:  2021-03       Impact factor: 1.429

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.